Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT-1 vs placebo vs donepezil for mild to moderate Alzheimer's disease
2004-002941-11Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mimopezil in Alzheimer's disease (AD) (4 arms), sponsored by Debiopharm. Primary endpoints: Safety and tolerability of ZT-1 (1.5 mg and 2 mg once daily) and Efficacy of ZT-1 (1.5 mg and 2 mg once daily) on cognitive function. Started Feb 2005; status: completed.
02
Drugs
mimopezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2004-002941-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002941-11.